骨质疏鬆症药物市场：按药物类型、给药途径、分销渠道、地区 - 规模、份额、前景和机会分析，2018-2026

骨质疏鬆症是一种与骨骼有关的疾病，它会削弱骨骼并增加骨折和骨折的风险。骨质疏鬆症的原因包括长期使用大剂量口服皮质类固醇、骨质疏鬆症家族史（尤其是父母有髋部骨折史）、低体重指数（BMI）以及大量饮酒和吸烟。骨质疏鬆症的治疗包括骨折的预防和治疗以及强健骨骼的药物治疗。治疗通常涉及药物，例如双膦酸盐，这是治疗骨质疏鬆症最常用的药物。此外，由于骨弱化雌激素水平降低，建议绝经后妇女接受激素治疗。

市场动态

在预测期内，新型骨质疏鬆症治疗药物的批准和上市预计将显着推动骨质疏鬆症治疗市场的增长。例如，2019 年 10 月，美国食品药品监督管理局（Food and Drug Administration）向生物技术公司 Pfenex 提交了 PF708 的新药申请（NDA），以特立帕□注射液为参考药物在 505（b）（2）监管途径下。）宣布批准。 FDA 批准的 PF708 与特立帕□注射液一样，适用于治疗某些骨折高风险患者的骨质疏鬆症。

此外，2020 年 8 月，跨国製药公司 Cadila Pharmaceuticals 宣布在印度推出 Forteo 的骨质疏鬆症生物仿製药 NuPTH。 Forteo 的生物仿製药用于治疗骨质疏鬆症和骨折风险增加的患者。 NuPTH 是一种生物仿製药，旨在为骨质疏鬆症患者提供具有成本效益的解决方案，并将作为易于使用的预填充一次性笔进行销售。

本研究的主要特点

• 它对全球骨质疏鬆症治疗市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模（十亿美元）和復合年增长率（CAGR%）。 .
• 解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
• 该研究还提供了有关市场驱动因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 基于公司亮点、产品组合、关键亮点、财务业绩和战略等参数的全球骨质疏鬆症治疗市场主要参与者的概况。
• 本研究涵盖的主要公司包括 Teva Pharmaceutical Industries Ltd.、DAIICHI SANKYO COMPANY, LIMITED、Amgen Inc.、Dr. Reddy's Laboratories Ltd.、Viatris Inc.、Ligand Pharmaceuticals Incorporated、Eli Lilly and Company、Asahi Kasei Corporation、F. Hoffmann-La Roche Ltd、EffRx Pharmaceuticals SA、Novartis AG、Merck & Co., Inc.、GSK plc 和 Pfizer Inc.
• 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 《全球骨质疏鬆症治疗市场》报告面向行业内的各种利益相关者，包括投资者和供应商、产品製造商、分销商、新进入者和财务分析师。
• 通过用于分析全球骨质疏鬆症治疗市场的各种战略矩阵，利益相关者可以轻鬆做出决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第2章市场展望

• 举报内容
  • 市场定义和范围
• 执行摘要
  • 市场快照：按药物类型
  • 按管理途径划分的市场概况
  • 市场快照：按分销渠道
  • 市场概况：按地区划分
• 连贯的机会图 (COM)

第 3 章市场动态、监管和趋势分析

• 市场动态
  • 驱动程序
  • 限制因素
  • 市场机会
• PEST 分析
• 管道分析
• 产品认证
• 产品发布
• 合作研究和收购
• 波特五力分析

第 4 章全球骨质疏鬆症药物市场 - COVID-19 影响分析

• 整体影响
• 对供需的影响
• COVID-19 对市场的影响

第 5 章全球骨质疏鬆症药物市场，按药物类型，2017-2030 年

• 双膦酸盐
• 降钙素
• 激素疗法
• 选择性雌激素受体调节剂 (SERM)
• 甲状旁腺激素相关蛋白（PTHrP）类似物药物
• Rank 配体 (RANKL) 抑製剂

第 6 章按给药途径分列的全球骨质疏鬆症药物市场：2017-2030 年

• 口服剂
• 注入
• 其他

第 7 章。按分销渠道分列的全球骨质疏鬆症药物市场：2017-2030

• 医院药房
• 零售药房
• 在线药店

第 8 章按地区分列的骨质疏鬆症药物全球市场，2017-2030 年

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海合会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第 9 章竞争格局

• Teva Pharmaceutical Industries Ltd.
• DAIICHI SANKYO COMPANY, LIMITED
• Amgen Inc.
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc.
• Ligand Pharmaceuticals Incorporated
• Eli Lilly and Company
• Asahi Kasei Corporation
• F. Hoffmann-La Roche Ltd
• EffRx Pharmaceuticals SA
• Novartis AG
• Merck & Co., Inc.
• GSK plc.
• Pfizer Inc.

第10章 章节

• 调查手法
• 关于出版社

Osteoporosis is a bone related disease that weakens bones and increases the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis - particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. Osteoporosis treatment involves preventing and treating fractures and using medication to strengthen bones. The treatment usually includes medications such as Bisphosphonates that are the most common drugs prescribed for osteoporosis. Furthermore, hormone therapy treatment is recommended for post-menopausal women, as they experience a drop in the levels of estrogen, which weakens the bones.

Market Dynamics

Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over the forecast period. For instance, in October 2019, the U.S. Food and Drug Administration had announced the approval of the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with teriparatide injection as the reference drug to Pfenex, a biotechnology company. Like teriparatide injection, the FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.

Moreover, in August 2020, Cadila Pharmaceuticals, a multinational pharmaceutical company, had announced the launch of NuPTH an osteoporosis biosimilar of Forteo in India. The Forteo biosimilar is used for treatment of osteoporosis and in patients with increased risk of fracture. The biosimilar NuPTH aims to be a cost effective solution for patients with osteoporosis and will be sold as an easy to use, pre-filled disposable pen.

Key features of the study:

• This report provides in-depth analysis of the global osteoporosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global osteoporosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market

Detailed Segmentation:

• Global Osteoporosis Treatment Market, By Drug Type:
  • Bisphosphonates
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
  • Calcitonin
  • Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Rank Ligand (RANKL) Inhibitor
• Global Osteoporosis Treatment Market, By Route of Administration:
  • Oral
  • Injectable
  • Others
• Global Osteoporosis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Osteoporosis Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• PEST Analysis
• Pipeline Analysis
• Product Approval
• Product Launch
• Collaboration-Acquisition
• Porter's Five Forces Analysis

4. Global Osteoporosis Treatment Market- COVID-19 Impact Analysis

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Osteoporosis Treatment Market, By Drug Type, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Bisphosphonates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
• Calcitonin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Selective Estrogen Receptor Modulators (SERMs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Rank Ligand (RANKL) Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Osteoporosis Treatment Market, By Route of Administration, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Osteoporosis Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Osteoporosis Treatment Market, By Region, 2017 - 2030, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• DAIICHI SANKYO COMPANY, LIMITED
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Dr. Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ligand Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Asahi Kasei Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• EffRx Pharmaceuticals SA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us